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OBJECTIVES The purpose of this study was to evaluate left atrial mechanical function recovery and plasma
atrial natriuretic peptide (ANP) release following successful cardioversion of persistent atrial
fibrillation (AF).
BACKGROUND Atrial fibrillation is characterized by functional deterioration, loss of atrial contraction, and
elevation of plasma ANP levels. The response of ANP release toward atrial mechanical
function after cardioversion of AF has not been fully examined.
METHODS We examined 29 patients with successfully cardioverted persistent AF in whom sinus rhythm
was maintained for at least 30 days after cardioversion. We assessed mechanical function of
the left atrium at 24 h and 7 and 30 days after cardioversion and evaluated plasma ANP level
at the same time. Atrial mechanical function was assessed during echocardiographic
examination by means of the peak velocity of the transmitral A-wave, early transmitral to
atrial flow velocity ratio, and atrial filling fraction (AFF). The plasma ANP level was
determined by the radioimmunoassay method.
RESULTS Plasma ANP levels were significantly reduced from 59.4  16.6 pg/ml to 31.1  9.2 pg/ml
at 24 h after successful cardioversion. Within 30 days, we noted progressive improvement of
atrial systolic function (increase in AFF from 21% to 31%, p  0.05). At the same time,
plasma ANP levels gradually increased from 31.1  9.2 pg/ml at 24 h to 36.9  12.8 pg/ml
on day 30 following cardioversion (p  0.05).
CONCLUSIONS Plasma ANP levels significantly decreased in patients with persistent AF after successful
cardioversion. In the 30 days after cardioversion, gradual elevation of plasma ANP
concentration was observed concomitantly with an increase of AFF. Plasma ANP release after
successful cardioversion of persistent AF might be due to recovery of atrial mechanical
function. (J Am Coll Cardiol 2003;41:1716–20) © 2003 by the American College of
Cardiology Foundation
Atrial fibrillation (AF) is primarily characterized by electri-
cal remodeling and functional deterioration. The inappro-
priately rapid ventricular response, loss of atrial contribution
to cardiac output, and atrial overloading lead to neurohor-
monal system activation (1).
Atrial natriuretic peptide (ANP), with its diuretic, natri-
uretic, and vasodilative actions, plays a major role in body
fluid hemostasis and blood pressure (BP) control, protecting
the organism from volume and pressure overload during
arrhythmia (2).
The electrical, mechanical, and hormonal remodeling
after cardioversion of persistent AF is related to the duration
of AF and is mostly reversible (3–5). The delayed improve-
ment in atrial contraction is associated with an initial
stunning in atrial mechanical function (6). During the
course of long-standing AF, a significant decline in ANP
levels (“endocrinologic silence”) has been described (7,8).
However, no previous study has systematically assessed the
influence of functional factors stimulating ANP secretion in
patients with nonrheumatic persistent AF after successful
cardioversion.
The aim of our study was to determine a time-course
improvement of atrial mechanical and endocrine function
after cardioversion of persistent AF and to assess the
relationship between transient left atrial mechanical dys-
function and ANP secretion.
METHODS
Study patients. We attempted direct-current cardioversion
in 42 consecutive patients with persistent AF. Cardioversion
was successful in 35 patients. However, in 6 of the 35
patients, AF reappeared within one month; 29 patients (21
men and 8 women; mean age 56.4 years) maintained sinus
rhythm within 30 days after cardioversion. There were no
significant differences, before cardioversion, in clinical,
echocardiographic, and hemodynamic data and plasma
ANP levels between the sinus rhythm group (n  29) and
patients with unsuccessful cardioversion or recurrence of
AF.
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All of the patients had been given oral anti-arrhythmic
drugs (beta-blockers, propafenone, or amiodarone) to pro-
tect them against arrhythmia recurrence. Anti-arrhythmic
treatment was initiated before cardioversion.
The known duration of AF ranged from 28 days to 24
months (mean 6.9 months). Atrial fibrillation was caused by
hypertension (n  12), ischemic heart disease (n  11), or
both (n  6). Eight of 29 patients were in New York Heart
Association functional class III, and 21 were in or class I or
II. All patients had controlled AF, with a mean heart rate
(HR) of about 86 beats/min, normalized BP, and effective
anticoagulation.
The control group in sinus rhythm comprised 11 subjects
compatible in terms of age, gender, and concomitant dis-
eases.
Direct-current cardioversion. After induction of general
anesthesia with intravenous fentanyl and etomidate, increas-
ing direct-current external shocks of 200, 300, and 360 J
were used until the highest energy (1,000 J) was reached or
sinus rhythm was achieved.
Echocardiographic studies. The assessments of left atrial
and ventricular dimensions and left ventricular ejection
fraction were performed immediately before and then 24 h
and 7 and 30 days after cardioversion. All measurements
were performed following the American Society of Echo-
cardiography recommendations (9). The transmitral flow
profile was recorded by continuous-wave Doppler echocar-
diography from the apical four-chamber view, with the
sample positioned between the tips of the mitral leaflets.
Peak velocities of early filling (E-wave) and atrial filling
(A-wave) were determined, and ratio of peak early filling
velocity to peak atrial systolic velocity was calculated.
Doppler signals were digitalized using a microcomputer
(IBM AT, Hewlett Packard Co., Andover, Massachusetts)
and consisted of manual tracing of the velocity curves.
Velocity-time integrals of the transmitral total and A-wave
of the Doppler flow pattern were determined. Atrial me-
chanical function was assessed according to Manning et al.
(10) and expressed as the percent atrial contribution to total
left ventricular filling (atrial filling fraction [AFF] %).
Blood sampling and hormone assay. Blood samples of
ANP were obtained from the antecubital vein in the supine
position after a resting period of 30 min just before
echocardiographic examination (before and then 24 h and 7
and 30 days after cardioversion). All specimens were col-
lected in tubes containing ethylenediaminetetra-acetic acid
(1.5 g/l) and protease inhibitor (Trasylol [aprotinin] 500
kU/ml). Plasma was separated by centrifugation for 20 min
at 4°C and kept at 35°C until measurement. Analysis of
ANP plasma level was performed by means of radioimmu-
noassay methods (Peninsula Laboratories Inc., Belmont,
California). The inter-assay coefficient of variation was 9%,
and the intra-assay coefficient was 6%. Informed, written
consent was obtained from each patient.
Statistical analysis. Data are expressed as the mean value
 SD (variables were normally distributed). Statistical
significance of serial changes in the plasma concentration of
ANP, echocardiographic variables, and hemodynamic data
during the study period was assessed by using the Student
paired t test and analysis of variance for repeated measures,
followed by the Scheffe´ F test. Correlations between two
parameters were tested by linear regression analysis using
the least-squares method. A level of p  0.05 was accepted
as statistically significant.
RESULTS
Echocardiographic studies. Left atrial and ventricular di-
mensions remained unchanged at 24 h after cardioversion of
AF. In the 30 days after cardioversion, left atrial volume
decreased and left ventricle ejection fraction increased sig-
nificantly compared with measurements before cardiover-
sion (102.5  24.9 ml vs. 86.6  25.8 ml [p  0.05] and
52.6  10.9% vs. 58.6  9.1% [p  0.05], respectively).
PULSED DOPPLER TRANSMITRAL RECORDINGS. Identifi-
able atrial filling waves on the pulsed Doppler transmitral
recordings performed 24 h after successful cardioversion
were seen in all 29 patients. The initial value of the mean
A-wave velocity, however, was significantly lower than
those values at 7 and 30 days (p  0.05) after cardioversion
or in those of control subjects (p  0.05). Thirty days after
cardioversion, the peak A-wave velocity had markedly
increased compared with 24-h data (0.28  0.11 vs. 0.42 
0.2, p  0.05). Twenty-four hours after cardioversion, AFF
was significantly lower than that in the control group (21.2
 8.7% vs. 33.2  7.9%, p  0.05). From 24 h to 30 days
after cardioversion, AFF increased significantly (21.2 
8.7% vs. 31.7  10.1%, p  0.05) (Fig. 1).
Plasma ANP levels. The mean plasma ANP level before
cardioversion was 59.4 16.6 pg/ml in the examined group
and 34.3  10.7 pg/ml in the control group (p  0.001).
The mean systolic BP at the time of tube collecting before
cardioversion was 126.9  14.5 mm Hg. At the same time,
the HR measured by electrocardiography was 82.1  8.5
beats/min and 74.7  9.8 beats/min in the examined and
control groups, respectively (p  NS). The HR decreased
24 h following cardioversion to 64.1  9.5 beats/min, but it
did not reach statistical significance (borderline significance:
p  0.06). Plasma ANP levels were significantly reduced
from 59.4  16.5 pg/ml to 31.4  15.0 pg/ml at 24 h
following cardioversion (p  0.001). The plasma ANP
concentration gradually increased from 24 h to 30 days after
cardioversion (31.4  15.0 pg/ml to 36.9  12.8 pg/ml, p
 0.05) (Fig. 1). The mean systolic BP and HR did not
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change during this period (115.6  14.9 mm Hg vs. 126 
13.4 mm Hg [p  NS] and 64.1  9.5 beats/min at 24 h
vs. 65.7  8.2 beats/min on day 30 [p  NS], respectively).
A significant positive linear correlation was found between
plasma ANP level and maximal atrial volume (r 0.60, p
0.05).
DISCUSSION
The left atrium is important in the maintenance of left
ventricular function and in hormonal secretion. After short
periods of AF, electrical remodeling and mechanical dys-
function are completely reversible, and normal values are
reached within two to three days after sinus rhythm recovery
(5). Atrial chamber and appendage “stunning” after electri-
cal cardioversion of AF is related to its duration (11). After
longer periods of AF, recovery from contractile dysfunction
may take several weeks to months (6,8).
In the present study, left atrial contractility increased
progressively, becoming comparable to values in the control
group by 30 days after successful cardioversion.
Atrial fibrillation is associated with activation of ANP.
Previous studies have demonstrated that plasma ANP levels
are markedly elevated in patients with chronic AF and
decrease substantially after conversion to sinus rhythm
(1,3,4). Although the trigger for release of ANP is still being
discussed, experimental and clinical studies have suggested
that atrial volume, pressure, and wall stretch are the main
determinants of ANP activation (1,10).
In our patients, left atrial dimensions were markedly
enlarged compared with controls. Within 30 days after
Figure 1. (Top) Changes in atrial filling fraction (AFF) after cardioversion in 29 patients with persistent atrial fibrillation (*p  0.05 vs. 24 h after
cardioversion). (Bottom) Changes in plasma atrial natriuretic peptide (ANP) level in 29 patients (*p  0.05 vs. 24 h after cardioversion).
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successful cardioversion, atrial volume significantly dimin-
ished. A relationship was found between plasma ANP levels
and atrial volumes. Our result confirms the hypothesis that
increased atrial volumes, with an associated increase in atrial
stretch, cause ANP secretion (12).
Atrial mechanical overload may lead to atrial qualitative
changes in electrical, mechanical, and neurohormonal func-
tions. Some studies have demonstrated that plasma ANP
levels in patients with AF were a function of time and were
lower among patients with AF of longer duration (7,8,13).
During the course of prolonged AF, extensive degenerative
changes (atrophy and fibrosis) of the atrial myocytes de-
velop, as found in biopsy specimens (14). The degeneration
or exhaustion of atrial cells that secrete ANP may be the
explanation for decreased plasma ANP levels among pa-
tients with long-standing AF. These findings suggest that
plasma ANP levels reflect the qualitative change of atrial
myocardium. We have shown recently that patients who
had an increase in plasma ANP levels from rest to peak
exercise before cardioversion had a better outcome (15).
In the present study, the mean plasma ANP concentra-
tion before cardioversion was nearly two times higher than
that in the control group and decreased significantly during
24 h after successful cardioversion of AF. From 24 h to 30
days, the plasma ANP level gradually increased. Other
variables, such as left atrial and ventricular dimension
(except for left atrial volume), HR, and systolic BP, did not
change during this period. The increase in ANP concentra-
tion from 24 h to 30 days after cardioversion was concom-
itant with an increase in AFF and might due to changes in
atrial mechanical function. There seems to be a significant
difference between the lack of mechanical function during
AF, when the highest ANP levels were observed, and the
atrial stunning during sinus rhythm immediately after car-
dioversion. Nevertheless, after successful cardioversion, re-
covery of atrial contraction is delayed and deranged mitral
and tricuspid valve closure and irregular ventricular rate are
reversed, which leads to an improvement of left ventricular
function, a reduction of volume overloading and filling
pressures, and a decrease in stretch of the atrial and
ventricular walls. Normalization of hormonal secretion in
conjunction with atrial contractility occurred in our study at
30 days after cardioversion. Our results confirm the hypoth-
esis that recovery of atrial mechanical function plays a role in
ANP secretion.
Comparable findings were reported by Fujiwara et al. (16)
in patients with mitral stenosis. They demonstrated an
increase in plasma ANP levels from 4 h to 5 days after
cardioversion of AF, owing to recovery of atrial mechanical
function, concomitantly with an increase in AFF. However,
Kalra et al. (17) investigated differences in the time course of
initial “stunning” in mechanical and endocrine function in
patients undergoing electrical cardioversion. Although en-
docrine function fully recovered by 7 days, mechanical
function (determined by sequential measurements of peak
A-wave velocity) continued to improve until 28 days.
A transient deficiency of the atria to produce ANP after
successful cardioversion was described by Arakawa et al. (3).
Passive leg elevation led to an increase in the mean pulmo-
nary artery wedge pressure but did not result in an increased
plasma ANP concentration. According to the authors, this
dysregulation of ANP release during an early period after
cardioversion of AF might be related to the decreased
sensitivity of the atrial receptors for ANP release following
volume overloading, as well as transient atrial contractile
dysfunction after cardioversion.
Pulmonary edema has been reported to be a potential
complication after successful cardioversion of AF (18).
Thus, left atrial systolic dysfunction associated with left
atrial overload mismatch, closely related to the impairment
of ANP release soon after cardioversion of AF, may lead to
pulmonary edema after cardioversion of AF. Further studies
will show whether atrial mechanical and endocrine function
parameters in patients with AF after cardioversion have
prognostic importance regarding the risk of stroke.
Neurohormonal activation in atrial pathophysiology rep-
resents a challenging, poorly understood problem of modern
arrhythmias and needs further investigations.
CONCLUSIONS
Plasma ANP levels significantly decreased in patients with
persistent AF after successful cardioversion and were com-
parable to those of the control group. Within 30 days after
cardioversion, atrial mechanical contractility improved grad-
ually, with a concomitant increase in ANP. The increase in
ANP from 24 h to 30 days after cardioversion may be due
to recovery of atrial mechanical function.
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